Ketek review scheduled
Executive Summary
FDA's Anti-Infective Drugs Advisory Committee will meet at the Marriott Washingtonian Center in Gaithersburg, Md., Jan. 8 at 8 a.m. to review Aventis' Ketek for three anti-infective indications. Aventis previously announced the meeting (1"The Pink Sheet" Nov. 4, p. 16). On Jan. 9, the committee will review the Center for Veterinary Medicine's proposed approach to ranking antimicrobial drugs relative to their importance in human medicine as a basis for risk assessments in development of new animal drugs...
You may also be interested in...
Aventis Ketek Will Return To FDA Advisory Committee Jan. 8
FDA's Anti-Infective Drugs Advisory Committee will review the safety profile of Aventis' Ketek (telithromycin) on Jan. 8, Exec VP-Commercial Operations Thierry Soursac told an investor conference call Oct. 29
CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings
FDA officials have said hiring could be slowed if an inflationary pay increase is not included in the agency budget, but CDER and CBER continue to add staff at a steady pace.
Medicare Reimbursement For Part B Drugs Is 48% Above 340B Prices To Hospitals, MedPAC Finds
New study updates past commission analyses and highlights the significant margin between Medicare payments for drugs and the prices paid by 340B-eligible providers.